Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR6 | P51684 | 8/20 | 0.51 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.45 |
| ▸ | CDK2 | P24941 | 2/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | SFRP1 | Q8N474 | 1/20 | 0.41 |
| ▸ | PRKCZ | Q05513 | 3/20 | 0.41 |
| ▸ | PRKD2 | Q9BZL6 | 3/20 | 0.41 |
| ▸ | CNR1 | P21554 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13090008 | 0.95 | CCR6 (0.51) | CCR6CCNA2CDK2ROCK2BRD4 | |
| SCHEMBL13087245 | 0.94 | CCR6 (0.44) | CCR6CCNA2CDK2JAK2JAK1 | |
| SCHEMBL13089944 | 0.92 | CCR6 (0.42) | CCR6CCNA2CDK2JAK2JAK1 | |
| SCHEMBL13087356 | 0.90 | CCR6 (0.46) | CCR6CCNA2CDK2JAK2JAK1 | |
| SCHEMBL13087793 | 0.89 | CDK2 (0.44) | CCR6CCNA2CDK2JAK2JAK1 | |
| SCHEMBL13089969 | 0.89 | ROCK2 (0.43) | CCR6CCNA2CDK2JAK2JAK1 | |
| SCHEMBL2424533 | 0.89 | ROCK2 (0.43) | CCR6CCNA2CDK2ROCK2BRD4 | |
| SCHEMBL13087525 | 0.88 | CCR6 (0.42) | CCR6CCNA2CDK2JAK2JAK1 | |
| SCHEMBL13087712 | 0.88 | ROCK2 (0.45) | CCR6CCNA2CDK2JAK2JAK1 | |
| SCHEMBL13087296 | 0.88 | ROCK2 (0.46) | CCR6ROCK2PRKCZPRKD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8299055-B2 | 8-substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-10-30 | — | — | US | disclosed |
| US-8299055-B2 | 8-substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-10-30 | — | — | US | disclosed |
| US-20100261701-A1 | 8-Substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-10-14 | — | — | US | disclosed |
| US-20100261701-A1 | 8-Substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261701-A1 | 8-Substituted isoquinoline derivative and the use thereof | RELA, NFKBIA, NFKB2 | CCR6 3313/4885CCNA2 920/4885CDK2 193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.